Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers

Trial Profile

Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary) ; Topotecan (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jun 2016 Planned number of patients changed from 60 to 240.
    • 04 Dec 2015 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2020 as per ClinicalTrials.gov record.
    • 22 Jul 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top